Supervisory board

MorphoSys AG Reports First Quarter 2024 Financial Results

Retrieved on: 
Monday, April 29, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Sale, FDA, Bone marrow, BET, Research and development, EDT, Investment, Safety, JAK, Food, EZH1, Research, Marketing, EZH2, Administration, ASCO, Novartis, Ruxolitinib, Patient, Supervisory board, Society, Acquisition, Operating cost, Annual general meeting, G&A, European Medicines Agency

MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.

Key Points: 
  • MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the first quarter of 2024.
  • The financial results presented for the first quarter of 2024 relate to continuing business operations of MorphoSys.
  • Full Year 2024 Financial Guidance:
    As a consequence of the sale and transfer of tafasitamab to Incyte on February 5, 2024, MorphoSys' 2024 financial guidance published on January 30, 2024, cannot be maintained and therefore was revoked.
  • MorphoSys Group Key Figures (IFRS, end of the first quarter: March 31, 2024)

NAGA’s Shareholders Approve the Merger With CAPEX.com With a Positive Vote of 99.81%

Retrieved on: 
Monday, April 22, 2024
Software, Personal Finance, Cryptocurrency, Finance, Professional Services, Technology, Apps, Applications, Fintech, Ecosystem, XETRA, Markets.com, AI, App, Pătrașcu, Shareholder, EGM, Supervisory board, Acquisition, Marketing, Super-app, NAGA Group

Key highlights from his presentation include:

Key Points: 
  • Key highlights from his presentation include:
    Market Expansion: Detailed plans to propel NAGA into new and untapped markets, broadening the company's global footprint and harnessing new customer segments.
  • This move is expected to significantly boost the company's market share and strengthen its position in the competitive financial technology landscape.
  • Securing this vote will allow us, after the regulatory approvals for the merger, to execute the new business plan.
  • After the merger, NAGA will be able to draw from the broader talent pool and local presence offered by the 9 local CAPEX offices.

Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors

Retrieved on: 
Thursday, April 18, 2024
Research, Infectious Diseases, FDA, Clinical Trials, Biotechnology, AIDS, Health, Science, Oncology, Biochemistry, Development, Bayer, HCV, Rutgers University, Biophysics, Communication, Baylor College of Medicine, Beneficial ownership, Infection, HIV, Name, Therapy, Harvard University, Publication, Research and development, Supervisory board, Drug development, Natural science, Doctor of Philosophy, University, Agriculture, Cancer, Bangladesh Technical Education Board, Gilead Sciences, Syntex, Patient, Pleasure, MBA, Annual general meeting, HBV, Kronos

Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).

Key Points: 
  • Vir Biotechnology, Inc. (“Vir” or “the Company”, Nasdaq: VIR) today announced the nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors (the “Board”) at its upcoming annual meeting of stockholders on May 29, 2024 (the “Annual Meeting”).
  • The nomination of the two new independent directors demonstrates Vir’s commitment to ongoing Board refreshment.
  • Marianne De Backer, M.Sc., Ph.D., MBA, Vir’s Chief Executive Officer, said: “We are incredibly excited about the prospect of adding such highly talented directors in Norbert and Ramy to the Board.
  • Previously, he served on the board of directors of Nimbus Therapeutics, a biotechnology company he helped found in 2009.

MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis

Retrieved on: 
Thursday, April 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Cancer, EDT, MorphoSys, Takeover, ADS, Novartis, Patient, Supervisory board, Acquisition

The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.

Key Points: 
  • The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as “Novartis”), recommending that shareholders accept the offer and tender their MorphoSys shares.
  • Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total equity value of € 2.7 billion (the “Takeover Offer”).
  • “The offer made by Novartis provides MorphoSys shareholders with an opportunity to realize significant value upfront and with certainty.
  • The MorphoSys Management Board and Supervisory Board joint reasoned statement, as well as other relevant information for shareholders, is available on the MorphoSys website at https://www.morphosys.com/en/investors/Novartis-TakeoverOffer .

VIA optronics AG Announces Intention to Voluntarily Delist its ADSs from the New York Stock Exchange

Retrieved on: 
Tuesday, April 9, 2024
Hardware, Audio, Video, Other Technology, Technology, Software, American depositary receipt, ADS, Supervisory board, Annual report, Security (finance)

VIA optronics AG (NYSE: VIAO) (“VIA” or the “Company”), a leading supplier of interactive display solutions, today announced its intention to voluntarily delist its American Depository Shares (“ADSs”) from the New York Stock Exchange (“NYSE”) and terminate its registration with the U.S. Securities and Exchange Commission (“SEC”).

Key Points: 
  • VIA optronics AG (NYSE: VIAO) (“VIA” or the “Company”), a leading supplier of interactive display solutions, today announced its intention to voluntarily delist its American Depository Shares (“ADSs”) from the New York Stock Exchange (“NYSE”) and terminate its registration with the U.S. Securities and Exchange Commission (“SEC”).
  • The Company today notified the NYSE of its intent to voluntarily delist its ADSs from the NYSE, pursuant to a resolution adopted by its Supervisory Board today.
  • Accordingly, VIA anticipates that the last day of trading of the ADSs on the NYSE will be on or about April 29, 2024.
  • As previously disclosed, the Company received notice from the NYSE that it is not currently in compliance with the continued listing standards of the NYSE.

SAP Announces Q1 2024 Results

Retrieved on: 
Monday, April 22, 2024
Cloud, AI, HR, Partnership, Infrastructure as a service, Unico, Growth, LyondellBasell, Vaillant Group, Commerce, NVIDIA, Annual report, SAP, Sumitomo Heavy Industries, ZF Friedrichshafen, Tax, Public Power Corporation, The Blind, Visa, Platform as a service, ERP, MTN, House, Dell, Supervisory board, Aldo Group, Moody's Investors Service, Teleology, Sky, Curtiss-Wright, Coca-Cola Europacific Partners, Software as a service, APJ, Platform, Share repurchase, AGM, Cintas

IFRS operating profit in the first quarter was impacted by a €2.2 billion restructuring provision associated with the 2024 transformation program.

Key Points: 
  • IFRS operating profit in the first quarter was impacted by a €2.2 billion restructuring provision associated with the 2024 transformation program.
  • As of March 31, 2024, SAP had repurchased 10,024,841 shares at an average price of €137.62 resulting in payouts of approximately €1.38 billion under the program.
  • In 2024, SAP is further increasing its focus on key strategic growth areas, in particular business AI.
  • Reflecting re-investments into strategic growth areas, SAP expects to exit 2024 at a headcount similar to year-end 2023.

Frank Elderson: “Know thyself” – avoiding policy mistakes in light of the prevailing climate science

Retrieved on: 
Thursday, April 18, 2024
European Convention, Reproduction, Failure, European Court, Face, Human rights, Frankfurt, Climate, United Nations, World Bank Group, Investment, Paris Agreement, International economics, Policy, Bank of Greece, Wildfire, Speech, Environment, United Nations Environment Programme, Science, ECB, Blog, Risk, Education, EIOPA, Communication, Drought, Ancient Greek, Climate change, Safety, Watcher, De Nederlandsche Bank, Procrastination, Depression, European Environment Agency, Green, Tourism, Knowledge, Research, Food, Private sector, Insurance, IPCC, Movement, European Central Bank, The, Temperature, Health, Uncertainty, Attention, Conference, Financial system, Supervisory board, Oracle, Bank, Fishery, Flood, Thought, DELFI, Water, World Bank, Persians, Government, International human rights law, Renewable energy

Stock market development and familiarity (language and distance) are considered key determinants for home bias.

Key Points: 
  • Stock market development and familiarity (language and distance) are considered key determinants for home bias.
  • The literature neglects however that investors often invest in foreign funds domiciled in financial centers.

EQS-News: 3U paves the way for anticipated growth spurt

Retrieved on: 
Wednesday, April 10, 2024
Managed services, Electricity, Annual, Primary energy, GEG, Tax, Growth, Construction, UUU, Supervisory board, Environment, 3U, Climate, DIY, Sale, Wind, Carbon, Plant, Investment, Kilowatt-hour, SHAC, Depreciation, ITC, Renewable energy

Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at EUR 5.2 million in the period under review (previous year: EUR 8.5 million).

Key Points: 
  • Earnings before interest, taxes, depreciation and amortisation (EBITDA) stood at EUR 5.2 million in the period under review (previous year: EUR 8.5 million).
  • We will also continue to focus on the topic of external growth.
  • The ITC segment raised revenue by 26.3 % overall to EUR 15.3 million in 2023 (previous year EUR 12.1 million).
  • Organic growth stood at 10.3% and is principally attributable to success in winning new customer business.

EQS-News: Resolutions of the Annual General Meeting of Sartorius AG

Retrieved on: 
Wednesday, April 10, 2024
Sartorius AG, Sartorius, Annual general meeting, PwC, Supervisory board

At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.

Key Points: 
  • At today’s virtual Annual General Meeting, the shareholders of Sartorius AG approved the proposals of the Executive Board and the Supervisory Board by a large majority, including the proposal to distribute a dividend of 0.74 euros per preference share and 0.73 euros per ordinary share.
  • This press release contains forward-looking statements about the future development of the Sartorius Group.
  • Sartorius assumes no liability for updating such statements in light of new information or future events.
  • Sartorius shall not assume any liability for the correctness of this translation.

EQS-News: WashTec AG: New revenue record and substantial 10.3% increase in EBIT with significant rise in free cash flow to €46.1m

Retrieved on: 
Wednesday, April 10, 2024
Annual, Annual report, Growth, Supervisory board, CFO, Supervision, Acquisition, Pharmaceutical industry

The year-on-year revenue growth was mainly due to the very positive performance in the chemicals business, where new customers were acquired.

Key Points: 
  • The year-on-year revenue growth was mainly due to the very positive performance in the chemicals business, where new customers were acquired.
  • Largely due to the implemented price increases and active cost management, EBIT rose by 10.3% to €41.9m (prior year: €38.0m).
  • Free cash flow increased significantly to €46.1m (prior year: €16.2m) despite the €9.5m acquisition of the site occupied by the American subsidiary.
  • The annual report for fiscal year 2023 and further information about WashTec can be found on the WashTec: Investor Relations Website .